INTRODUCTION
Aurora-A is a mitotic serine/threonine kinase, which is evolutionally conserved and is localized at the centrosome. 1 Activation of Aurora-A is required for mitotic entry, centrosome maturation and separation and G2 to M transition. 2 It has been shown that Aurora-A is frequently amplified and/or overexpressed in breast carcinoma. 3 In animal models, oestrogen-induced rat breast cancers expressed high levels of Aurora-A and displayed centrosome amplification and aneuploidy. 4 Moreover, mouse mammary tumour virus-driven Aurora-A transgenic mice developed breast tumours and genetic instability occurred before tumorigenesis in mammary epithelial cells. 5 In addition, recent studies have shown that Aurora-A promotes distant metastases only in ERa-positive breast cancer cells. 6, 7 These findings indicate the critical role of Aurora-A in mammary carcinogenesis. However, the role of Aurora-A in endocrine therapy resistance and ERa signalling remains largely unknown.
ERa is a hormone-dependent nuclear transcription factor expressed in B70% of breast tumours. 8 The binding of oestrogen to ERa results in ERa dimerization and its recruitment to the oestrogen-responsive elements (EREs) on the promoters of ERa target genes. 9, 10 Because ERa has a major role in the development and progression of breast cancer, current endocrine therapies for breast cancer are mainly based on targeting the ERa signalling pathway. Among the endocrine therapies targeting ERa, the selective oestrogen receptor modulator tamoxifen, which inhibits breast cancer growth through competitive binding of ERa, has been the principal endocrine therapy for breast cancer for the past 30 years. 11 However, tamoxifen resistance presents a major challenge in treating the disease. [12] [13] [14] ERa is a key determinant of breast cancer susceptibility to endocrine therapy and posttranslational modifications of ERa often lead to endocrine resistance. 15 The phosphorylation of ERa has long been implicated in modulating endocrine response 16, 17 and has been shown to influence ERa-binding potential and gene expression profiles, 16 resulting in tamoxifen resistance.
In this study, we demonstrated a critical role of Aurora-A in regulation of tamoxifen sensitivity. Aurora-A inhibitor MLN8237 synergized with tamoxifen to inhibit cell growth and cell survival and to overcome tamoxifen resistance. Furthermore, Aurora-A interacted with ERa and phosphorylated ERa-Ser167/Ser305. The phosphorylation of ERa by Aurora-A resulted in activation of ERa in the absence of oestrogen. These data indicate that Aurora-A has an important role in regulation of ERa activity and tamoxifen resistance, and thus could be a therapeutic target in breast cancer endocrine therapy. In addition, these findings underscore the potential of MLN8237 as either an independent or concurrent agent in tamoxifen-resistant breast cancer and the pERa-Ser167/Ser305 as potential clinical biomarkers in Aurora-A inhibitor therapy.
RESULTS

Knockdown of Aurora-A reverses tamoxifen resistance and ectopic expression of Aurora-A renders cells resistant to tamoxifen
Previously, studies showed frequent overexpression/activation of Aurora-A in breast cancer and a critical role of Aurora-A in mammary epithelial cell immortalization and transformation. 5, 18 When we examined Aurora-A expression in a panel of breast cancer cell lines, we found elevated levels of Aurora-A protein and p-Aurora-A-T288 in tamoxifen-resistant BT474 and MCF7-TamR cells as compared with tamoxifen-responsive MCF7 cells ( Figure 1a ). These findings prompted us to assess the role of Aurora-A in tamoxifen resistance. We initially assessed the tamoxifen sensitivity in three ERa-positive and one ERa-negative cell lines (Supplementary Figure S1 ) and subsequently knocked down Aurora-A in BT474 and MCF7-TamR cells using two siRNAs against different coding regions of Aurora-A (Figure 1b and Supplementary Figure S2a ). Following incubation for 2 days, the cells were treated with and without increasing doses of tamoxifen for 72 h and then subjected to MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromides), Annexin V/FACS and colony formation assays. In agreement with previous reports, tamoxifen alone had minimal effect on cell death and colony growth in tamoxifen-resistant BT474 and MCF7-TamR cells. 19 However, knockdown of Aurora-A significantly reduced cell survival and colony formation, and enhanced tamoxifen anti-tumour effects in both BT474 and MCF7-TamR cell lines (Figures 1c-e and  Supplementary Figures S2b and 2c) . To further examine the role of Aurora-A in tamoxifen sensitivity, we ectopically expressed Aurora-A in tamoxifen-responsive MCF7 cells (Figure 2a ). The cells transfected with empty vector were used as controls. Following treatment with tamoxifen, we found that overexpression of Aurora-A rendered MCF7 cells resistant to tamoxifen ( Figures  2b-d ). As controls, we evaluated the effects of Aurora-A on response to tamoxifen in ERa-negative cells. Aurora-A was knocked down and ectopically expressed in MDA-MB-468 and MDA-MB-231 cells, respectively. After administration of tamoxifen, cell viability and colony formation were found to be no different Figure 1 . Knockdown of Aurora-A sensitizes tamoxifen-resistant cells to tamoxifen. (a) Western blot was performed with indicated antibodies in a panel cell lines. Note: elevated Aurora-A was detected in tamoxifen-resistant MCF7-TamR and BT474 cells. (b) BT474 cells were transfected with two siRNAs of Aurora-A and control siRNA targeting eGFP. After 72 h of incubation, immunoblot was carried out with the indicated antibodies. (c-e) Aurora-A siRNA-and control siRNA-treated BT474 cells were treated with and without tamoxifen (0-2.0 mM). Total cell viability (c), apoptosis (d) and cell growth (e) were assessed by MTT assays, Annexin V/FACS and focus formation, respectively. Experiments were repeated three times, each experiment was performed in triplicates. Error bars represent mean þ s.d. The asterisks denote significance (*Po0.05 and **Po0.01).
between Aurora-A-manipulated and control-siRNA/vector-treated cells in both ERa-negative cell lines (Supplementary Figure S3 ). These data indicate that Aurora-A has a role in tamoxifen resistance and could be a critical therapeutic target for overcoming the resistance in ERa-positive breast cancer cells.
Aurora-A inhibitor MLN8237 cooperates with tamoxifen and overcomes tamoxifen resistance in vitro and in vivo
Since tamoxifen-resistant MCF7-TamR and BT474 cells expressed high levels of Aurora-A and knockdown of Aurora-A reduced the resistance, we further investigated whether Aurora-A inhibitor MLN8237, which is currently in clinical trial, 20 is able to overcome tamoxifen resistance and to cooperate with tamoxifen. We first treated MCF7-TamR and BT474 cells with various concentrations of MLN8237 and tamoxifen alone and in combination and monitored cell survival. Figures 3a and c show that MLN8237 alone inhibited p-Aurora-A-T288 and caused a dose-dependent inhibition of cell survival with IC 50 values of B4.0 mmol/l, whereas tamoxifen alone had much less effect on cell survival with IC 50 values of greater than 5 mmol/l. However, combination treatment of cells with Aurora-A inhibitor and tamoxifen resulted in significant cell death with IC 50 values of tamoxifen from 45 (in the absence of MLN8237) to 0.1 mmol/l (in the presence of 0.5 mmol/l MLN8237; Supplementary Figure S4 ). In addition, we found that combination of MLN8237 and tamoxifen increased cleavage of PARP, caspase-7 (MCF7-TamR) or caspase-3 (BT474) more significantly than either one alone ( Figure 3b ). Therefore, MLN8237 sensitized MCF7-TamR and BT474 cells to tamoxifen. To further examine whether MLN8237 synergizes with tamoxifen, we treated cells with a combination of MLN8237 and tamoxifen and used Calcusyn software to generate Fa-CI plots as described under methods. Supplementary Figure S4 shows that almost all the experimental points have CI values o1.0. The resulting Fa-CI plot curve falls well below one for the effect range, showing that the combination of MLN8237 and tamoxifen is synergistic in tamoxifen-resistant MCF7-TamR and BT474 cells.
We next determined whether Aurora-A inhibitor MLN8237 overcomes tamoxifen resistance in vivo. Orthotopic tumours were established by injection of BT474 cells into the mammary fat pads of athymic nude mice. After implanted tumours reached B100 mm 3 in size, the mice were randomized in four groups (seven mice/group): vehicle, tamoxifen alone, MLN8237 alone and both tamoxifen and MLN8237. As control, orthopotic tumours with tamoxifen-sensitive MCF7 cells were also established and administered with tamoxifen and vehicle (Supplementary Figure S5 ). The mice were treated for 12 consecutive days and the tumour growth was monitored for an additional 1 week ( Figure 3d ). Although the control group tumour reached 1500 mm 3 in volume at the end point of the assay, the MLN8237-treated tumours grew much slower than control and tamoxifen-treated groups. Treatment with tamoxifen alone completely inhibited MCF7 tumour growth but only caused an B10% reduction in BT474 tumour size compared with the control group (Figure 3d and Supplementary Figure S5 ), whereas the combination of both MLN8237 and tamoxifen significantly Following treatment of MCF7-TamR and BT474 cells with and without various concentrations of MLN8237 and tamoxifen for 72 h, cells were processed for MTT assay (c) and western blot (b, note: cleaved caspase-7 for MCF7-TamR and cleaved caspase-3 for BT474). (d-g) MLN8237 alone and in combination with tamoxifen inhibited tamoxifenresistant tumour growth in orthotopic breast cancer model. BT474 cells were injected to mammary fat pads of nude mice. When tumour reached B100 mm 3 , mice were treated with MLN8237 or/and tamoxifen as described in 'Materials and methods' . The tumour growth was monitored (d). At the end of experiment, the tumour weight was calculated (e). Representative tumour tissues were proceeded to western blot (f ) and immunohistochemical staining (f ) with indicated antibodies.
repressed BT474 tumour growth (Figure 3d ). Similarly, the BT474 tumour weight in MLN8237-and the combination-treated groups was dramatically reduced as compared with control and tamoxifen-treated groups (Figure 3e ). Immunoblotting analysis of the representative tumours revealed that p-Aurora-A-T288 was inhibited by MLN8237 and that PARP cleavage was induced in the tumours treated with MLN8237 alone and combination of MLN8237 and tamoxifen ( Figure 3f ). Moreover, immunostaining with cleavage caspase-3 and Ki-67 antibodies showed that inhibition of Aurora-A alone and combination with tamoxifen significantly activated caspase-3 and inhibited proliferation ( Figure 3g ). Taken together, these data indicate that Aurora-A inhibitor MLN8237 not only overcomes tamoxifen resistance but also synergizes with tamoxifen in vitro and in vivo.
Aurora-A induces ERa transactivation activity
Post-translational modification of ERa has been shown to be one of the major mechanisms in tamoxifen resistance. 21, 22 Thus, we next investigated whether Aurora-A regulates ERa transactivation activity. Reporter assay was performed by introducing ERa responsive element reporter (ERE-Luc) combined with HA-Aurora-A into MCF7 cells, and the results showed that Aurora-A strongly induced ERa transactivation activity in a dose-dependent manner ( Figure 4A ). In addition, the reporter activity induced by E2 was further increased by expression of Aurora-A (Supplementary Figure  S6a ). However, E2-but not Aurora-A-induced ERa activation was inhibited by tamoxifen (Supplementary Figure S6b ). Furthermore, the effect of Aurora-A on ERE-Luc activity was evaluated in ERa-negative MDA-MB-231 cells. Following transfection of ERE-Luc and ERa together with and without Aurora-A, luciferase assay revealed that expression of ERa alone moderately induced ERE-Luc activity. However, the reporter activity was significantly stimulated by co-expression of ERa and Aurora-A ( Figure 4B ). These data suggest that Aurora-A not only activates ERa activity but also enhances E2 action and that Aurora-A-induced ERa activation could not be inhibited by tamoxifen.
Aurora-A interacts with and phosphorylates ERa
To determine the mechanism by which Aurora-A induces ERa transactivation activity, we initially performed co-immunoprecipitation in MDA-MB-231 cells following transfection of GFP-ERa and HA-Aurora-A. Figure 4C shows that HA-Aurora-A interacted with GFP-ERa. We next examined whether endogenous ERa and Aurora-A form a complex. Co-immunoprecipitation was carried out in MCF7-TamR cells, which express elevated Aurora-A and ERa ( Figure 1a ). As shown in Figure 4D , ERa was readily detected in Aurora-A immunoprecipitates and vice versa. Furthermore, glutathione S-transferase (GST) pull-down assay revealed that GST-Aurora-A but not GST could pull down the recombinant ERa ( Figure 4E ). These data indicate that Aurora-A directly binds to ERa. To determine whether Aurora-A colocalizes with ERa, we performed immunofluorescence staining in MCF7-TamR cells with anti-ERa and -Aurora-A antibodies and we found that Aurora-A colocalized with ERa not only in the nucleus but also in the centrosome ( Figure 4F ).
We next investigated whether Aurora-A phosphorylates ERa. In vitro Aurora-A kinase assay was performed by incubation of fulllength human recombinant ERa with and without recombinant Aurora-A. Figure 5a shows that ERa was highly phosphorylated in the reaction containing Aurora-A. To determine whether Aurora-A phosphorylates ERa in vivo, MDA-MB-231 cells were co-transfected with Myc-ERa and either HA-Aurora-A or vector. After labelling with [ 32 P]-orthophosphate for 3 h, ERa was immunoprecipitated with anti-Myc antibody and the immunoprecipitates were separated by SDS-PAGE. Following exposure of an x-ray film, we observed that phosphorylation of ERa was induced by Aurora-A ( Figure 5b ).
We further defined the amino acid(s) of ERa that are phosphorylated by Aurora-A. In vitro Aurora-A kinase assay was carried out using GST fusion proteins containing different portions of ERa as substrates (Supplementary Figure S7a ). As ERa/1-200 and ERa/1-318 but not ERa/1-150 were phosphorylated by Aurora-A, a potential phosphorylation site(s) was mapped to the amino acid 150-318 region of ERa (Supplementary Figure S7b ). Mass spectrometry analysis revealed serine-167 (Ser167), Ser212 and Ser305 as putative Aurora-A phosphorylation sites. To verify whether these three serine residues are phosphorylated by Aurora-A, we further created three different GST-ERa fusion proteins that contain Ser167, Ser212 or Ser305 and their serinealanine mutation S167A, S212A and S305A individually (Supplementary Figure S7a) . In vitro kinase assays revealed that Aurora-A phosphorylated wild-type GST-ERa-S167, even it is not a perfect match with Aurora-A phosphorylation consensus motif, 23 and -S305 but not GST-ERa-S212, -S167A, and -S305A (Supplementary Figure S7c ). Furthermore, in vivo [ 32 P]orthophosphate labelling and western blotting analysis revealed that Aurora-A phosphorylation of wild-type ERa but not ERa-S167A/ S305A (ERa-2A) mutant (Figures 5c and d ), suggesting that Ser167 and Ser305 of ERa are phosphorylated by Aurora-A. These findings were further confirmed by immunoblotting of Aurora-A overexpressing MCF7 and Aurora-A knocking down BT474 cells ( Figure 5e ) as well as of cold in vitro Aurora-A kinase reaction (Supplementary Figure S7d ) using specific phospho-ERa-Ser167 and -Ser305 antibodies. In addition, we observed that Aurora-A inhibitor MLN8237 significantly inhibited p-ERa-Ser167/Ser305 levels in MCF7-TamR and BT474 cells ( Supplementary Figures  S8a and b ) and the xenografts (Supplementary Figure S8c ). Based on these findings, we conclude that ERa-Ser167 and -Ser305 are phosphorylated by Aurora-A in vitro and in vivo.
Aurora-A induced ERa transactivation activity and CCND1 expression via phosphorylation of ERa-Ser167 and Ser305
Since Aurora-A induces ERa transactivation, we next investigated whether Aurora-A-induced ERa activity depends on phosphorylation of ERa-Ser167 or/and Ser305. ERa-negative MDA-MB-231 cells were transfected with wild-type ERa, ERa-S167A, ERa-S305A or ERa-S167A/ S305A (ERa-2A) together with ERE-Luc. Reporter assay showed that expression of Aurora-A significantly induced wild-type ERa but not ERa-S167A/S305A transactivation activity (Figure 6a ). Furthermore, Aurora-A also stimulated ERa-S167A-and ERa-S305A-induced ERE-Luc activity to a much lesser extent than wild-type ERa (Figure 6a ).
As CCND1 (cyclin D1) is a major target of ERa and overexpression of CCND1 has been implicated in tamoxifen resistance, 24, 25 we also examined whether Aurora-A induces CCND1 expression and, if present, whether the induction depends on phosphorylation of ERa-Ser167/SerS305. ERa-positive MCF7 and ERa-negative MDA-MB-231 cells were transfected with Aurora-A. Following 72 h of incubation, semi-quantitative RT-PCR and immunoblot analyses revealed that mRNA and protein levels of CCND1 were induced by Aurora-A in MCF7 but not in MDA-MB-231 cells (Figure 6b and Supplementary Figure S9 ). Furthermore, knockdown of Aurora-A decreased CCND1 expression in BT474 cells (Figure 6c ), suggesting Aurora-A induction of CCND1 through ERa. To determine whether Aurora-A phosphorylation of ERa mediates this action, we expressed wild-type ERa, ERa-S167A/S305A, ERa-S167A and ERa-S305A together with and without Aurora-A in MDA-MB-231 cells. As shown in Figures 6d-f , co-expression of Aurora-A and wild-type ERa significantly increased CCND1 protein and mRNA levels and ERa transactivation and DNAbinding activity towards the CCND1 promoter. However, Aurora-A failed to exert these effects when co-transfected with ERa-S167A/ S305A. Expression of ERa-S167A or ERa-S305A partially inhibited Aurora-A-induced CCND1 (Figures 6d and e ). In addition, we examined the relationship between Aurora-A and CCND1 mRNA levels in patient samples from gene expression omnibus gene expression datasets and found a significant positive correlation of Aurora-A with CCND1 expression in ERa-positive but not ERanegative breast cancers (Supplementary Figure S10) . Taken together, these data indicate that Aurora-A induces ERa and ERa-targeted gene CCND1 through phosphorylation of Ser167 and Ser305. Supplementary  Table S1 ). Further, p-ERa-Ser167 and p-ERa-Ser305 were detected in 88 and 71 tumours, respectively, which include 34 cases with positive p-ERa-Ser167/Ser305 (Figure 7c ). Of the 34 tumours with elevated levels of p-ERa-Ser167/Ser305, 32 (94.1%) also had elevated Aurora-A (Po0.00001; Figure 7d ). The other two cases with elevated p-ERa-Ser167/Ser305 could have resulted from activation of other kinases (Figure 8 ). Further analyses showed that Aurora-A expression level, p-ERa-Ser167 and p-ERa-Ser305 status were not related to tumour size, lymph node metastasis, tumour stage and grade ( Supplementary Table S1 ). However, p-ERa-Ser167/Ser305 and p-ERa-Ser167 alone, but not p-ERa-Ser305, are significantly associated disease-free survival (DFS) (Supplementary Figure S11a-c and Supplementary Table S2 ). All 32 patients with elevated Aurora-A and positive p-ERa-Ser167/ Ser305 relapsed from tamoxifen/nolvadex treatment and had poor DFS (Supplementary Figure S11d) . Notably, elevated levels of Aurora-A were found to be significantly associated with DFS (Figure 7d and Supplementary Table S2 ).
Upregulation of Aurora-
To further confirm these findings, we took advantage of the available gene expression datasets summing up to 854 ERa-positive primary breast cancers with associated clinical data, including endocrine therapy, disease recurrence and survival ( Supplementary  Table S3 ). We defined each data set into two groups of tumours with, respectively, high and low level of expression of Aurora-A (Supplementary Figure S12) . Strikingly, the univariate Kaplan-Merier survival analysis revealed that the group expressing high levels of Aurora-A displayed a significant higher probability of developing recurrence when compared with the 'low' group (P-values ranged from 0.0064 to 3E-01, depending on the datasets; Figure 7e , Supplementary Figure S12 and S13 and Supplementary Table S4 ). In addition, the KM Plotter database (http://www.kmplot.com; Gyorffy et al. 26 ) analysis of breast cancers also showed that Aurora-A levels were significantly associated with recurrence-free survival in ERapositive breast cancers treated with endocrine therapy (Figure 7f and Supplementary Table S5 ) but not in ERa-negative and basal breast tumours (Supplementary Figure S14 and Supplementary  Table S5 ). As antiestrogen therapy was used in ERa-positive tumours collected in these datasets, the recurrence largely represents the resistance to endocrine therapy. Therefore, these data suggest that elevated Aurora-A has significant implication in recurrence of ERapositive breast cancers, which are mostly due to Aurora-A inducing endocrine therapy resistance by phosphorylation of ERa.
DISCUSSION
Here we show that overexpression of Aurora-A sufficed to induce tamoxifen resistance, whereas inhibition of Aurora-A by small molecule-inhibitor MLN8237 or small interfering RNA knockdown overcame the resistance. Previous reports demonstrated that overexpression/activation of Aurora-A is a recurrent event in human breast cancer. 3 A recent study showed that Aurora-A promotes distant metastases by inducing epithelial-tomesenchymal transition in ERa-positive breast cancer cells, 6 suggesting a link between Aurora-A and ERa, which has a critical role in disease progression in ERa-positive breast cancer. Our data showed that Aurora-A directly interacted with ERa and phosphorylated ERa-Ser167/Ser305 in vitro and in vivo (Figures 4  and 5 ). Coexistence of overexpression of Aurora-A and phospho-ERa-Ser167/Ser305 was detected in tamoxifen-resistant breast cancer cells and primary tumours with poor prognosis (Figures 1  and 7c and Supplementary Figure S11d ). Furthermore, data mining analysis of B2400 breast cancers revealed that elevated Aurora-A was significantly associated with short recurrence-free survival only in ERa-positive and antiestrogen-treated breast cancers (Figures 7e and f and Supplementary Figure S12 -S14, and Supplementary Tables S4 and S5 ). Thus, these findings indicate that ERa is a bona fide substrate of Aurora-A and that elevated level of Aurora-A is a causal factor of endocrine therapy resistance and a valuable prognostic marker in ERa-positive breast cancer.
Previous studies showed that at least 80% of tamoxifenresistant breast tumours retain ERa expression 11 and that phosphorylation of ERa by protein kinases is one of the major mechanisms that cause the resistance. Serine-167, which is located in the N-terminal activation function 1 domain (AF-1) of ERa, has been shown to be phosphorylated by Akt, S6K1, pp90rsk as well as IKBKE, and the phosphorylation of Ser167 leads to increase of ERa transactivation activity. [27] [28] [29] [30] In a small study based on tamoxifen-treated breast cancer patients, 31 the p-ERa-Ser167 was correlated with increased tamoxifen sensitivity. 32 In contrast, other results have indicated that the phosphorylation of ERa-Ser167 is linked to reduce tamoxifen sensitivity. 27, 28 In this study, our data show that p-ERa-Ser167 is associated with poor prognosis (Supplementary Figure S11b) . Serine-305 is located in the hinge region of ERa and the phosphorylation of this residue by PKA and PAK1 has been shown to result in ERa transcriptional activation of its target genes. 33, 34 In addition, phosphorylation of Ser305 is correlated with tamoxifen resistance, whereas it is not associated with DFS. [33] [34] [35] [36] [37] We showed that Aurora-A phosphorylates both Ser167 and Ser305 of ERa, which is significantly related with short DFS (Figures 5 and 7e , Supplementary Figure S11a and S11d) and significantly induces ERa transactivation activity and CCND1 expression ( Figure 6 ). Mutation of Ser167 and Ser305 to alanine abrogated the effect of Aurora-A on ERa activity and CCND1 expression ( Figure 6 ). Collectively, these data suggest that Aurora-A-induced ERa activation, tamoxifen resistance and disease recurrence could be largely through phosphorylation of Ser167 and Ser305 (Figure 8 ).
Aurora-A is a centrosome kinase, however, it has been shown to also phosphorylate the molecules outside the centrosome, including TRF1, RalA, p53, HDAC6 and so on. [38] [39] [40] [41] Our data showed that Aurora-A colocalized with ERa in both the nucleus and centrosome (Figure 4f and Supplementary Figure S15b ). We also observed the colocalization of p-ERa-Ser167 and p-ERa-Ser305 with Aurora-A in the centrosome (Supplementary Figure  S15a) , implying that Aurora-A also phosphorylates ERa within the centrosome. The function of ERa in the centrosome is currently unknown. Further studies are required to characterize the role of ERa in Aurora-A-induced centrosome amplification.
Finally, several small molecule-inhibitors of Aurora kinases have been developed and are currently undergoing preclinical and early clinical testing. In particular, MLN8237 is a novel, orally bioavailable, second-generation selective inhibitor of Aurora-A. MLN8237 has exhibited efficacy against solid tumours and haematologic malignancies in preclinical models and is currently undergoing clinical evaluation in haematological and solid cancers. 42, 43 In this report, we showed that MLN8237 not only inhibited tamoxifen-resistant breast cancer cell survival and tumour growth but also cooperated with tamoxifen in cell culture and orthotopic breast cancer model (Figure 3 and Supplementary Figure S4 ). In addition, MLN8237 abrogated Aurora-A phosphorylation of ERa-Ser167 and -Ser305 (Supplementary Figure S8) . These data underscore the potential of MLN8237 as either an independent or concurrent agent in tamoxifen-resistant breast cancer and the pERa-Ser167/Ser305 as potential clinical biomarkers in Aurora-A inhibitor therapy. 
MATERIALS AND METHODS
Reagents and plasmids
Antibodies for Aurora-A and p-Aurora-A-T288 were purchased from Abcam, Cambridge, MA, USA and Cell Signaling, Boston, MA, USA, respectively. ERa and p-ERa-Ser167 antibodies were from Upstates, Lake Placid, NY, USA and Santa Cruz, Dallas, TX, USA. Antibody for p-ERa-Ser305 was purchased from Millipore, Billerica, MA, USA. Anti-HA and -Flag antibodies were from Sigma, St Louis, MO, USA. Recombinant ERa and Aurora-A proteins were from Stressgen, Victoria, BC, Canada and Cell Signaling, respectively. HA-tagged (pHM6) Aurora-A, GFP-tagged and Myc-tagged full-length and truncated ERa mutants as well as GST-ERa constructs were previously described. 18, 27 Mutations of ERa-Ser167/Ser305 to alanine (ERa-2A) were prepared with QuikChange Site-directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) and were confirmed by sequencing analysis. Small interfering RNAs of Aurora-A were from Qiagen, Valencia, CA, USA. Tamoxifen and Aurora-A inhibitor MLN8237 were obtained from Sigma and Selleckchem, Houston, TX, USA, respectively.
Cell culture and transfection Human breast cancer cell lines (T47D, BT474, MDA-MB-468, MDA-MB-231 and MCF7) were obtained from ATCC. MCF7-TamR was generated by chronic low-dose treatment with tamoxifen. 44 The cells were grown in RPMI-1640 or DMEM medium supplemented with 10% fetal bovine serum or in phenol red-free DMEM with charcoal-stripped serum. Transfections were performed using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) following the manufacturer's instruction. Frozen and formalin-fixed paraffin embedded human primary breast cancer and normal breast tissues were obtained from the Tissue Procurement Facility at Moffitt Cancer Center under an approved IRB protocol.
Western blot, immunoprecipitation, immunohistochemistry and Immunofluorescence staining Western blot, immunoprecipitation, immunohistochemistry and immunofluorescence were performed as previously described. 40 Briefly, cell lysates were prepared in a lysis buffer and then subjected to immunoprecipitation and/or immunoblots with antibodies indicated in the Figure legend (Figures 1-7) . For immunohistochemistry, breast cancer sections were immunostained with anti-Aurora-A (1:200), anti-ERa (1:250) and anti-ERa-Ser167/Ser305 (1:200) antibodies. The expression of Aurora-A and ERa was evaluated and scored as previously described. 7 Immunofluorescence staining was carried out by fixing cells with 10% formalin/10% methanol for 20 min and permeabilized in 1% NP-40 in phosphate-buffered saline. Cells were then blocked by 10% normal goat serum in phosphatebuffered saline and incubated with primary antibodies against Aurora-A and ERa followed by secondary antibodies. The DNA was counterstained with 4 0 ,6-diamidino-2-phenylindole.
Luciferase reporter assay Cells were transiently transfected with ERa-Luc or CCND1-Luc, Aurora-A, wild-type or mutant ERa and b-galactosidase. The amount of DNA in each transfection was kept constant by the addition of empty pHM6 vector. After 48 h of transfection, luciferase activity was measured using a luciferase assay reagents (Promega). Luciferase activities were normalized with respect to parallel bgalactosidase activities, to correct for differences in transfection efficiency. b-galactosidase assays were performed using the b-Galactosidase Enzyme Assay System (Promega, Madison, WI, USA).
Mass spectrometry, GST Pull-down, in vitro kinase assay and in vivo [ 32 P]Pi cell labelling Mass spectrometry was performed as previously described. 27 Glutathione-Sepharose beads coupled with recombinant GST-Aurora-A or GST were incubated with recombinant ERa (Abcam) in a binding buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 1 mk MgCl 2 , 1% Triton-X-100) for 2 h at 4 1C. After washing the beads three times with the binding buffer, proteins bound to the beads were analysed by 10% SDS-PAGE followed by immunoblotting with ERa antibody.
In vitro Aurora-A kinase assay was performed by incubation of recombinant Aurora-A and recombinant ERa, as a substrate, in an in vitro kinase buffer for 25 min and followed by SDS-PAGE. 18 For in vivo labelling, MDA-MB-231 cells were transfected with ERa and together with and without HA-Aurora-A. After serum starvation overnight, cells were labelled with [ 32 P]Pi (0.5 mCi/ml) in phenol red-free MEM without phosphate for 4 h. ERa was immunoprecipitated and separated in SDS-PAGE. The phospho-ERa was detected and quantified.
RT-PCR and chromatin immunoprecipitation RT-PCR and chromatin immunoprecipitation assays were performed as previously described. 27 Primers are: ERa, 5 0 -GGTGCC ACCTGTGGTCCACCTG-3 0 (sense) and 5 0 -CTTCACTTGTGGCCCAGAT AGG-3 0 (antisense); GAPDH, 5 0 -CATGTTCGTCATGGGTGTGAACCA-3 0 (sense) and 5 0 -AGTGATGGCATGGACTGTGGTCAT-3 0 (antisense); CCND1, 5 0 -GAACAGAAGTGCGAGAAGGAG-3 0 (sense), and 5 0 -AGG CGGTAGTAGGACAGGAAG-3 0 (antisense). For chromatin immunoprecipitation assay, the primers for CCND1 were used as following: forward ( À 1039) AACAAAACCAATTAGGAACCTT, reverse ( À 770) ATTTCCTTCATCTTGTCCTTCT. The PCR products were analysed by electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining.
Colony formation, cell viability, apoptosis assays and synergy analysis Colony formation, MTT and apoptotic assays were performed as previously described. 28 Each experiment was repeated three times in triplicate. The results are expressed as the enrichment factor relative to the untreated controls.
The synergistic effects of drug combinations were evaluated with Calcusyn software (Biosoft, Northfield, IL, USA). This software uses the Chou-Talalay combination index method, which is based on the median-effect equation, itself a derivation from the massaction law. 45 For this analysis, Drug1 was combined with Drug2 at a constant ratio determined by IC 50 Drug1/IC 50 Drug2. We entered the resulting proliferation data, along with the data obtained from single-drug treatments, into Calcusyn to determine a combination index value (CI) for each combination point, which quantitatively defines additivity (CI ¼ 1.0), synergy (CIo1.0) and antagonism (CI41.0). The resulting values were used to construct a plot of CI values over a range of fractions affected (Fa-CI plot).
Orthotopic breast cancer mouse model Experimental procedures involving animals were reviewed and approved by the Institutional Animal Care and Use committee. Animal care was in accordance with institution guidelines. Cells (5 Â 10 6 ) were injected into mammary fat pads of 6-week-old female nude mice (Charles River, Wilmington, MA, USA). Tumour growth was monitored twice weekly by caliper measurements (L Â W Â D). When the tumours reached the average size of 100 mm 3 , the mice were divided into four groups, each with seven mice and an even distribution of tumour sizes and treated as follows. Tamoxifen (at a dose of 5 mg) and Aurora-A inhibitor MLN8237 (at a dose of 30 mg/kg in a final formulation in 10% 2-hydroxypropyl-b-cyclodextrin/1% sodium bicarbonate) were orally given alone and in combination daily for 26 days. Control group was orally given 100 ml vehicle control daily.
Breast cancer datasets
To assess the relation of overexpression of Aurora-A with recurrence of ERa-positive breast cancer treated with endocrine therapy, 674 ERa-positive breast cancers that were treated with antiestrogen agents were analysed in the KM Plotter database (http://www.kmplot.com; Supplementary Table S5 ). We also collected four different datasets from ( Supplementary Table S1 ). For each data set, we performed survival analysis to test whether the Aurora-A levels are associated with recurrence. Each data set has been processed independently from the other to preserve the original differences among the various studies (for example, patient cohort, microarray type, sample processing protocol and so on). We downloaded ERa-positive breast cancer gene expression datasets with clinical information from Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/GEO/), or author's individual web pages. Supplementary Table S3 reports the complete list of datasets and their sources. The datasets included both affymetrix and dual- Aurora-A in tamoxifen resistance XQ Zheng et al channel complimentary DNA microarray platforms. When CEL files were available, expression values were generated from intensity signals using the RMA algorithm; values have been background adjusted, normalized using quantile normalization and expression measure calculated using median polish 7 summarization.
Statistic analysis
Statistical significance of differences between groups was analysed by unpaired Student's t-test. The correlation of Aurora-A with ERa phosphorylation was examined by w 2 -test. Hazard ratios and 95% confidence intervals (95% CI) were estimated using the Cox proportional hazards model. Recurrence-free survival time was calculated as the time between diagnosis and any of the events: locoregional recurrence, distant metastasis or breast cancer death. Recurrence-free survival time distributions were compared with the log-rank test and plots were drawn using the Kaplan-Meier technique. Multivariate analysis of recurrence rates and breast cancer mortality rates was done with Cox proportional hazard regression, a method also used for the interaction analysis of different factors. All analyses were performed using the SPSS 11.5 Statistical Software and Pp0.05 was considered to be statistically significant.
